InvestorsHub Logo
Followers 16
Posts 1561
Boards Moderated 0
Alias Born 02/27/2014

Re: None

Tuesday, 11/10/2020 6:41:19 PM

Tuesday, November 10, 2020 6:41:19 PM

Post# of 2223
FDA Approves XARACOLL® (bupivacaine HCl) Implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults


ATHLONE, Ireland, Aug. 31, 2020 -- Innocoll Holdings Limited, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, announced today that the US Food and Drug Administration (FDA) has approved Xaracoll® for acute postsurgical pain relief for up to 24 hours in adults following open inguinal hernia repair, a painful and commonly-performed surgery.1





https://www.gurnetpointcapital.com/news/fda-approves-xaracollr-bupivacaine-hcl-implant-non-opioid-drug-device-treatment-option-acute


Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.